Abstract:e18082 Background: EGFR mutation and EGFR gene-copy number are two main EGFR-related biomarkers that have been studied in major clinical trials. However, The association of EGFR gene-copy number with mutation and predictive values to EGFR-TKIs treatment in clinically unselected Chinese patients with advanced NSCLC remain to be unclear. We analyze the relationship between EGFR biomarkers status and clinical outcome in the patients received EGFR-TKI therapy. Methods: Total 102 Chinese patients who received EGFR-TKIs therapy were included in this study. Biomarkers included EGFR mutation (DHPLC), EGFR gene-copy number (fluorescence in situ hybridization). Results: Among 102 patients, 32 (31%) had high EGFR gene-copy number. The objective response rate (ORR), disease control rate, progression-free survival (PFS) and median survival time (MST) in the patients with high EGFR gene-copy number were 37.04%,74.07%, 5.13 and 13.20 months, respectively, closed to those with low EGFR gene-copy number (29.33%, 64% 4.75 and 14.70, respectively; p > 0.05). EGFR mutation was detected in 46 out of 102 patients (45%). No relationship was evidenced between EGFR gene-copy number and EGFR mutation (Interaction test p = 0.302). According to EGFR gene-copy number and EGFR mutation status, the patients were divided to four subgroups (FISH+/Mutation-, FISH+/Mutation+, FISH-/Mutation-, FISH-/Mutation+). ORR of four subgroup were 33.33%, 40%, 41% and 20.45%, respectively (p = 0.205). The patients with both EGFR wild-type and low gene-copy number (FISH-/Mutation -) presented poorer ORR than those with EGFR mutation or/and high gene-copy number (20.45% vs 39.66%, p = 0.041). PFS and OS were longer in the patients with co- existing EGFR mutation and high EGFR gene-copy number (7.87 ms, 16.90 ms, respectively) than other three subgroups, but difference didn't reach statistical significance (p = 0.233, p = 0.339). Conclusions: The association was not found between EGFR gene-copy number and mutation in this patient population.The patients with coexisting EGFR mutation and high EGFR gene-copy number had potential better predicting value to EGFR-TKI. No significant financial relationships to disclose.

The Predictive Values of Mutation Patterns, Concurrent Mutations and Efficacy of Different Generations of EGFR-TKIs in Advanced Non-Small Cell Lung Cancer Harboring Non-Resistant Uncommon EGFR Mutations.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

The Use of Mutation-Specific Antibodies in Predicting the Effect of EGFR-TKIs in Patients with Non-Small-cell Lung Cancer

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Treatment of Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: New Evidence and Treatment

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

Mutation Abundance Affects the Efficacy of Egfr Tyrosine Kinase Inhibitor Readministration in Non-Small-Cell Lung Cancer with Acquired Resistance

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy

Predicting Significance of EGFR Mutation Existing in Tissues and Plasma Concuurrently or Alone to EGFR–tyrosine Kinase Inhibitors (Egfr-Tkis) for Advanced Non-Small Cell Lung Cancer.

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)

[Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer]

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis

Intratumoral Heterogeneity of EGFR Mutation and Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

A Novel Point Mutation in Exon 20 of Egfr Showed Sensitivity to Erlotinib

The Relationship Between EGFR Gene Copy Number and EGFR Mutation and Clinical Predicting Significance in the Chinese Patients with Advanced Non-Small Cell Lung Cancer Patients.